Capromab is a Murine IgG1 monoclonal 7E11-C5.3 antibody that recognizes prostate specific membrane antigen (PSMA – also known as glutamate carboxypeptidase 2) from prostate cancer cells and normal prostate tissue. When linked to pendetide, capromab is used as a chelating agent for the radionuclide Indium In-111 during imaging to evaluate the extent of prostate cancer.

Protein structure

Protein chemical formula

Not Available

Protein average weight

Not Available

Sequences

Not Available

Synonyms

(111In)-Capromab pendetide
Indium (111In) capromab pendetide
Indium 111 Capromab Pendetide
Indium In 111 capromab pendetide

External IDs

CYT-356 / Cytogen 356

Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Unlock Additional Data
ProstaScint Kit for the Preparation of Indium In 111 Capromab Pendetide	Kit	0.5 mg/1mL		Jazz Pharmaceuticals	1996-10-28	Not applicable

Additional Data Available

Application Number

A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

Learn more

Product Code

A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

Learn more

International/Other Brands

ProstaScint (Cytogen Corp.)

Categories

UNII

BDO5072GRX

CAS number

145464-28-4

Pharmacology

Indication

For diagnosis of prostate cancer and detection of intra-pelvic metastases.

Associated Conditions

Prostate Cancer

Pharmacodynamics

Binds to the prostate-specific membrane antigen, which is a cell surface protein generally overexpressed in prostate tissues and prostate cancers. The radioactive Indium 111, which is covalently attached to the antibody, allows radiodiagnostic detection of PSMA expressing cells and tumors.

Mechanism of action

Binds selectively to cell-surface prostate-specific membrane antigen (PSMA) expressed on prostate tissues and tumors.

Target	Actions	Organism
AGlutamate carboxypeptidase 2	other/unknown	Humans

Unlock Additional Data

Additional Data Available

Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more

Additional Data Available

Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more

Additional Data Available

Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more

Absorption

Not Available

Volume of distribution

4 ± 2.1 L

Protein binding

Not Available

Metabolism

Most likely removed by opsonization via the reticuloendothelial system or by human antimurine antibody production

Route of elimination

Approximately 10% of the administered radioisotope dose is excreted in the urine during the 72 hours following intravenous infusion.

Half life

Not Available

Clearance

42 +/- 22 mL/hr

Toxicity

Not Available

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction
Unlock Additional Data
16-Bromoepiandrosterone	16-Bromoepiandrosterone may decrease effectiveness of Capromab pendetide as a diagnostic agent.
19-norandrostenedione	19-norandrostenedione may decrease effectiveness of Capromab pendetide as a diagnostic agent.
5-androstenedione	5-androstenedione may decrease effectiveness of Capromab pendetide as a diagnostic agent.
Abciximab	The risk or severity of adverse effects can be increased when Abciximab is combined with Capromab pendetide.
Abituzumab	The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Abituzumab.
Abrilumab	The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Abrilumab.
Adalimumab	The risk or severity of adverse effects can be increased when Adalimumab is combined with Capromab pendetide.
Adecatumumab	The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Adecatumumab.
Aducanumab	The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Aducanumab.
Afelimomab	The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Afelimomab.

Additional Data Available

Extended Description

Extended description of the mechanism of action and particular properties of each drug interaction.

Learn more

Severity

A severity rating for each drug interaction, from minor to major.

Learn more

Evidence Level

A rating for the strength of the evidence supporting each drug interaction.

Learn more

Action

An effect category for each drug interaction. Know how this interaction affects the subject drug.

Learn more

Food Interactions

Not Available

References

General References

Link [Link]
Link [Link]
Link [Link]

External Links

PubChem Substance: 46506263
ChEMBL: CHEMBL2108285
Therapeutic Targets Database: DAP001049
PharmGKB: PA164745489
Wikipedia: Indium_(111In)_capromab_pendetide

ATC Codes

V09IB04 — Indium (111in) capromab pendetide

FDA label

Download (1.65 MB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Completed	Diagnostic	Prostate Cancer	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

EUSA Pharma Inc.

Dosage forms

Form	Route	Strength
Kit		0.5 mg/1mL

Prices

Unit description	Cost	Unit
Prostascint kit	1584.0USD	kit

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Not Available

Properties

State

Liquid

Experimental Properties

Property	Value	Source
melting point (°C)	61 °C (FAB fragment), 71 °C (whole mAb)	Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)

Taxonomy

Description: Not Available
Kingdom: Organic Compounds
Super Class: Organic Acids
Class: Carboxylic Acids and Derivatives
Sub Class: Amino Acids, Peptides, and Analogues
Direct Parent: Peptides
Alternative Parents: Not Available
Substituents: Not Available
Molecular Framework: Not Available
External Descriptors: Not Available

Targets

Details1. Glutamate carboxypeptidase 2

Kind: Protein
Organism: Humans
Pharmacological action: Yes
Actions: Other/unknown

General Function: Tetrahydrofolyl-poly(glutamate) polymer binding
Specific Function: Has both folate hydrolase and N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity. Has a preference for tri-alpha-glutamate peptides. In the intestine, required for the uptake of fola...
Gene Name: FOLH1
Uniprot ID: Q04609
Uniprot Name: Glutamate carboxypeptidase 2
Molecular Weight: 84330.015 Da

References

Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D, Bander NH: In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. 2000 Sep 15;60(18):5237-43. [PubMed:11016653]
Sodee DB, Nelson AD, Faulhaber PF, Maclennan GT, Resnick MI, Bakale G: Update on fused capromab pendetide imaging of prostate cancer. Clin Prostate Cancer. 2005 Mar;3(4):230-8. [PubMed:15882479]
Gregorakis AK, Holmes EH, Murphy GP: Prostate-specific membrane antigen: current and future utility. Semin Urol Oncol. 1998 Feb;16(1):2-12. [PubMed:9508077]
Sodee DB, Ellis RJ, Samuels MA, Spirnak JP, Poole WF, Riester C, Martanovic DM, Stonecipher R, Bellon EM: Prostate cancer and prostate bed SPECT imaging with ProstaScint: semiquantitative correlation with prostatic biopsy results. Prostate. 1998 Nov 1;37(3):140-8. [PubMed:9792131]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Drug created on June 13, 2005 07:24 / Updated on June 04, 2019 04:51